{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044599","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.438712+00:00","generated_at":"2026-05-30T01:43:05.085250+00:00","sec_items":["7.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InspireMD Q3 revenue record $1.81M (+16.3% YoY); net loss $7.89M; submits PMA to FDA for CGuard Prime","bullets":["Revenue record $1.81M, up 16.3% YoY; gross margin 22.9% down from 28.1% due to higher costs.","Net loss $7.89M ($0.16/share) vs $5.18M ($0.15/share) in Q3 2023; operating expenses rose 46% to $8.88M.","Submitted PMA to FDA for CGuard Prime carotid stent; targets U.S. approval in H1 2025.","IDE approved for CGUARDIANS II pivotal study of CGuard Prime for TCAR procedures.","Cash and marketable securities $40.4M at Sept 30, 2024; new Miami HQ to support U.S. launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044599","json":"https://secwatch.observer/filing/0001493152-24-044599.json","markdown":"https://secwatch.observer/filing/0001493152-24-044599.md","text":"https://secwatch.observer/filing/0001493152-24-044599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224044599/0001493152-24-044599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224044599/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:43:05.085250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}